Aurobindo Pharma

Aurobindo Pharma reported a strong quarter with PAT of INR 910Current reported value: 910. No comparable prior figure is available in the source record. crore, supported by improving Pen G yields and a favorable government MIP policy on key antibiotics. The company is ramping Pen G production to over 10,000 metric tonsCurrent 10,000 metric tons. Reported change: +138% vs prior year average. annualized, with EBITDA breakeven already achieved. Europe continues double-digit growth, and the U.S. injectables business grew 17%Current 17%. Reported change: +17% YoY. despite the ongoing Eugia warning letter. Management guided for EBITDA margins in the 20-21% range for FY26 and expects meaningful contributions from Dayton and Raleigh facilities from FY27. Key risks include the timing of the Eugia warning letter resolution and potential delays in the Lannett acquisition.